- Hyoscine, widely used as an anticholinergic agent for preventing motion sickness, gastrointestinal cramps, and postoperative nausea, is becoming an essential therapeutic component across both prescription and over-the-counter pharmaceutical markets due to its effectiveness, rapid action, and growing availability in oral and transdermal forms
- The escalating demand for hyoscine is primarily fueled by increasing global travel contributing to motion sickness prevalence, a rising geriatric population experiencing gastrointestinal disorders, and expanding use in palliative care for managing secretion control
- North America dominated the hyoscine market with the largest revenue share of 37.8% in 2024, characterized by strong healthcare infrastructure, widespread awareness of antiemetic treatments, and the presence of leading pharmaceutical players. The U.S. has seen substantial demand growth driven by consumer preference for non-invasive treatment options and increased availability of transdermal patches
- Asia-Pacific is expected to be the fastest growing region in the hyoscine market during the forecast period due to growing healthcare access, increasing disposable incomes, and rising awareness of gastrointestinal and motion-related conditions
- Hyoscine Butyl Bromide segment dominated the hyoscine market with a market share of 75.5% in 2024, driven by its widespread use in treating gastrointestinal spasms and strong over-the-counter availability across global markets
